Clinical Trials
32 trialsNCT04895709 2026-06-04
A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors
Bristol-Myers Squibb
Phase 1/2 Recruiting
NCT04981119 2026-06-02
BASECAMP-1
A2 Biotherapeutics Inc.
Recruiting
NCT06465069 2026-05-22
NEXUS-01
Eli Lilly and Company
Phase 1 Recruiting
NCT07555210 2026-05-06
Pilot Study of Bone Mineral Density Changes During Anti-PD-1 Immunotherapy
Vanderbilt-Ingram Cancer Center
Phase NA Recruiting
NCT07115043 2026-04-23
A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors
AstraZeneca
Phase 1/2 Recruiting
NCT06270706 2026-04-20
A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
Pliant Therapeutics, Inc.
Phase 1 Recruiting
NCT07523529 2026-04-13
SELECT-2CAR
Beijing Biotech
Phase 1/2 Recruiting
NCT07517198 2026-04-08
Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid Tumors
Exscientia AI Limited
Phase 1 Recruiting
NCT06451497 2026-04-02
This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Toripalimab in Patients With Advanced Solid Tumors
Zumutor Biologics Inc.
Phase 1 Recruiting
NCT06422455 2026-03-18
Access to Genetic Testing in Underserved Patients With Cancer
University of Southern California
Phase NA Recruiting
NCT04585750 2026-03-12
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
PMV Pharmaceuticals, Inc
Phase 1/2 Recruiting
NCT05269381 2026-03-12
PNeoVCA
Mayo Clinic
Phase 1/2 Recruiting
NCT04485013 2026-02-18
TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers
Tizona Therapeutics, Inc
Phase 1 Recruiting
NCT07327489 2026-01-08
ELEPHAS-05
Elephas
Recruiting
NCT06399757 2026-01-07
A Study to Investigate APL-5125 in Adults With Advanced Solid Tumors
Apollo Therapeutics Ltd
Phase 1/2 Recruiting
NCT06781983 2026-01-07
Safety and Tolerability of IPH4502 in Patients With Advanced Solid Tumors
Innate Pharma
Phase 1 Recruiting
NCT06999187 2026-01-07
A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas
Dren Bio
Phase 1 Recruiting
NCT06022029 2025-12-24
ON-5001
OncoNano Medicine, Inc.
Phase 1 Recruiting
NCT07258563 2025-12-02
TASTY-steering
University Medical Center Groningen
Phase NA Recruiting
NCT05706129 2025-10-20
A Study to Assess Safety, Tolerability and Imaging Characteristics of [68Ga]Ga-DPI-4452 and to Assess Safety, Tolerability, and Efficacy of [177Lu]Lu-DPI-4452 in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors
ITM Oncologics GmbH
Phase 1/2 Recruiting
NCT04954599 2025-10-07
Phase 1/2 Clinical Trial of CP-506 (HAP) in Monotherapy or With Carboplatin or ICI
Maastricht University Medical Center
Phase 1/2 Recruiting
NCT03915678 2025-10-06
AGADIR
Institut Bergonié
Phase 2 Recruiting
NCT05329532 2025-09-17
ModiFY
Scancell Ltd
Phase 1/2 Recruiting
NCT05107674 2025-09-09
A Study of NX-1607 in Adults With Advanced Malignancies
Nurix Therapeutics, Inc.
Phase 1 Recruiting
NCT06682793 2025-09-09
DENALI-1
A2 Biotherapeutics Inc.
Phase 1/2 Recruiting
NCT05086692 2025-07-09
ABILITY-1
Medicenna Therapeutics, Inc.
Phase 1/2 Recruiting
NCT05078047 2025-06-05
MOIO
UNICANCER
Phase 3 Recruiting
NCT06337084 2025-05-22
Diagnostic Efficacy and Dosimetry of MNPR-101-DFO*-89Zr in Patients With Solid Tumors
Monopar Therapeutics
Phase 1 Recruiting
NCT06617169 2025-05-21
Dose-Escalation of MNPR-101-PCTA-177Lu in Solid Tumors
Monopar Therapeutics
Phase 1 Recruiting
NCT04510129 2025-03-12
A Multicenter Cancer Biospecimen Collection Study
Cofactor Genomics, Inc.
Recruiting
NCT04787042 2024-11-15
Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067
Simcha IL-18, Inc.
Phase 1/2 Recruiting
NCT05037825 2022-04-27
PARADIGM
VastBiome
Recruiting